|
Aug 28
|
Is Johnson & Johnson (JNJ) The Best Dividend Paying Stock To Buy According to Quant Hedge Fund AQR?
|
|
Aug 28
|
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
|
|
Aug 28
|
LifeNet launches newest bone allograft gel with Johnson & Johnson
|
|
Aug 28
|
Johnson & Johnson (JNJ): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
|
Aug 27
|
EC upgrades approval for J&J’s Rybrevant/chemotherapy combination in NSCLC
|
|
Aug 27
|
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
|
|
Aug 27
|
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
|
|
Aug 27
|
Biosense Webster completes enrolment for Omnypulse Platform trial
|
|
Aug 27
|
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
|
|
Aug 27
|
RA Capital-backed startup raises $100M; UCB sells China business
|
|
Jul 31
|
FDA approves J&J’s multiple myeloma therapy
|
|
Jul 30
|
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
|
|
Jul 30
|
If You Invested $1000 In Johnson & Johnson Stock 20 Years Ago, How Much Would You Have Now?
|
|
Jul 30
|
Do Fundamentals Have Any Role To Play In Driving Johnson & Johnson's (NYSE:JNJ) Stock Up Recently?
|
|
Jul 29
|
Big Pharma Rallies and Moves Past Obesity
|
|
Jul 27
|
Why Wall Street is unfazed by Medicare drug pricing threat
|
|
Jul 27
|
Could Johnson & Johnson's Troubles With Talc Lawsuits Finally Be Coming to an End?
|
|
Jul 25
|
'Never going to be the same': How Nvidia is trying to revolutionize healthcare
|
|
Jul 25
|
AC Immune wins FDA fast track for Alzheimer’s vaccine
|
|
Jul 25
|
Sandoz launches ustekinumab biosimilar in Europe
|